Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.
Sayaka Blickenderfer is a medical and science editor and writer with more than 10 years of experience. She edits and prepares scientific manuscripts and grant proposals for submission. Intestinal ...